These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36439135)

  • 1. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
    Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
    Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
    Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
    Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
    Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
    Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
    Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
    Chen YB; Mohty M; Zeiser R; Teshima T; Jamy O; Maertens J; Purtill D; Chen J; Cao H; Rossiter G; Jansson J; Fløisand Y
    Nat Med; 2024 Aug; 30(8):2277-2287. PubMed ID: 38844797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
    Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
    Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
    Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
    Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
    Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.
    Zu Y; Gui R; Li Z; Wang J; Li P; Liu Y; Dong X; Zhou J
    Ther Adv Hematol; 2024; 15():20406207241276982. PubMed ID: 39247427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.
    Fukuta T; Muramatsu H; Yamashita D; Sajiki D; Maemura R; Tsumura Y; Yamamori A; Imaya M; Wakamatsu M; Nishikawa E; Narita K; Kataoka S; Taniguchi R; Narita A; Nishio N; Takahashi Y
    Int J Hematol; 2023 Sep; 118(3):411-417. PubMed ID: 37074509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
    Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
    Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
    Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.
    Malard F; Loschi M; Huynh A; Cluzeau T; Guenounou S; Legrand F; Magro L; Orvain C; Charbonnier A; Panz-Klapuch M; Desmier D; Mear JB; Cornillon J; Robin C; Daguindau E; Bilger K; Vehreschild MJGT; Chevallier P; Labussière-Wallet H; Mediavilla C; Couturier MA; Bulabois CE; Camus V; Chantepie S; Ceballos P; Gaugler B; Holler E; Doré J; Prestat E; Gasc C; Plantamura E; Mohty M
    EClinicalMedicine; 2023 Aug; 62():102111. PubMed ID: 37654670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

  • 17. [Steroid-refractory gastrointestinal acute graft-versus-host disease treated with vedolizumab and ruxolitinib in a pediatric patient with therapy-related acute myeloid leukemia].
    Nagasawa S; Yamada A; Kinoshita M; Kamimura S; Tanaka H; Nishikawa T; Okamoto Y; Moritake H
    Rinsho Ketsueki; 2023; 64(1):23-29. PubMed ID: 36775302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Outcomes of Bacterial Bloodstream Infections during Acute Graft-versus-Host Disease Involving the Gastrointestinal Tract after Hematopoietic Cell Transplantation.
    Petersen J; Lindner C; Hakki M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1648-1653. PubMed ID: 31002988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
    Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.